ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Single-cell dissection of pleural and systemic immunity uncovers pathogen-specific immune reprogramming in tuberculosis versus lung adenocarcinoma.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To dissect how malignant versus infectious pleural disease reshapes local and systemic immunity, we compared lung adenocarcinoma with tuberculosis using matched pleural effusions and peripheral blood from patients and healthy controls using single cell transcriptome analysis and TCR clonotype tracking. Th1/17 polarized pro-inflammation dominating TB effusions, while their precursors, the recently activated CD4 T cells, adopt an antitumor trajectory in LUAD, but their recruitment and clonal expansion were effectively suppressed. In both diseases, CD8⁺ T cells diverged into GZMH⁺ and GZMK⁺ subsets. The former served as the antitumor killer cells but suppressed by multiple anti-inflammatory signals especially from the extracellular matrix in LUAD. The later could serve as stem-like precursors. MAITs and class-switched B cells both exhibited higher levels of activation and expanded in TB. Myeloid cells were mostly recovered from peripheral bloods and showed heightened activation in TB, upregulating TNFRSF14, TNFRSF13B, and pro-inflammatory cytokines (CXCL2, CXCL3, IL1), while LUAD featured immunosuppressive signals including MDK-NCL, FN1-CD44, and THBS1-CD47. Cell-cell communication highlighted LUAD-enriched outgoing interaction strengths by myeloid cells including monocytes and DCs, through IL16 and VISFATIN signaling, which strongly corelated with survivals. In conclusion, both pleural effusions and peripheral blood from TB and LUAD exhibit significant distinct immune landscapes. These results delineate disease-specific molecular mechanisms underlying immune regulation in pleural malignancies and infections.
Indexed as
Identifiers
41865158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.